JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hines, R. N.
Right arrow Articles by McCarver, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hines, R. N.
Right arrow Articles by McCarver, D. G.

Vol. 300, Issue 2, 355-360, February 2002

The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative Enzymes

Ronald N. Hines and D. Gail McCarver

Birth Defects Research Center, Departments of Pediatrics and Pharmacology/Toxicology, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin

Although some patterns are beginning to emerge, our knowledge of human phase I drug-metabolizing enzyme developmental expression remains far from complete. Expression has been observed as early as organogenesis, but this appears restricted to a few enzymes. At least two of the enzyme families that are expressed in the fetal liver exhibit a temporal switch in the immediate perinatal period (e.g., CYP3A7 to CYP3A4/3A5 and FMO1 to FMO3), whereas others show a progressive change in isoform expression through gestation (e.g., the class I alcohol dehydrogenases). Many of the phase I drug-metabolizing enzyme exhibit dynamic perinatal expression changes that are regulated primarily by mechanisms linked to birth and secondarily to maturity. A few of these enzymes are not detectable until well after birth, suggesting that birth is necessary but not sufficient for the onset of expression (e.g., CYP1A2). Tissue-specific expression adds to the complexity during ontogeny. For example, CYP3A7 expression is restricted to the fetal liver. However, with few exceptions, complete temporal relationship information during development is not known. Furthermore, most studies have concentrated on hepatic expression and much less is known about extrahepatic developmental events.

0022-3565/02/3002-0355$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 PediatricsHome page
L. G. Spector, S. E. Puumala, S. E. Carozza, E. J. Chow, E. E. Fox, S. Horel, K. J. Johnson, C. C. McLaughlin, P. Reynolds, J. V. Behren, et al.
Cancer Risk Among Children With Very Low Birth Weights
Pediatrics, July 1, 2009; 124(1): 96 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
K. J. S. Anand, B. J. Anderson, N. H. G. Holford, R. W. Hall, T. Young, B. Shephard, N. S. Desai, B. A. Barton, and for the NEOPAIN Trial Investigators Group
Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial
Br. J. Anaesth., November 1, 2008; 101(5): 680 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. G. Spector, A. J. Hooten, and J. A. Ross
Ontogeny of Gene Expression: A Changing Environment for Malignancy
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1021 - 1023.
[Full Text] [PDF]

Home page
 Br J AnaesthHome page
K. Allegaert, J. N. van den Anker, J. N. de Hoon, R. H. N. van Schaik, A. Debeer, D. Tibboel, G. Naulaers, and B. J. Anderson
Covariates of tramadol disposition in the first months of life
Br. J. Anaesth., April 1, 2008; 100(4): 525 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. A. Felmlee, H.-K. Lon, F. J. Gonzalez, and A.-M. Yu
Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice
Drug Metab. Dispos., February 1, 2008; 36(2): 435 - 441.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
C. Duret, S. Gerbal-Chaloin, J. Ramos, J.-M. Fabre, E. Jacquet, F. Navarro, P. Blanc, A. Sa-Cunha, P. Maurel, and M. Daujat-Chavanieu
Isolation, Characterization, and Differentiation to Hepatocyte-Like Cells of Nonparenchymal Epithelial Cells from Adult Human Liver
Stem Cells, July 1, 2007; 25(7): 1779 - 1790.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Shao, P. L. Stapleton, Y. S. Lin, and E. P. Gallagher
Cytochrome P450 and Glutathione S-Transferase mRNA Expression in Human Fetal Liver Hematopoietic Stem Cells
Drug Metab. Dispos., January 1, 2007; 35(1): 168 - 175.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
I. Warrier, W. Du, G. Natarajan, V. Salari, and J. Aranda
Patterns of drug utilization in a neonatal intensive care unit.
J. Clin. Pharmacol., April 1, 2006; 46(4): 449 - 455.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. S. Anand, K.-B. Kim, S. Padilla, S. Muralidhara, H. J. Kim, J. W. Fisher, and J. V. Bruckner
ONTOGENY OF HEPATIC AND PLASMA METABOLISM OF DELTAMETHRIN IN VITRO: ROLE IN AGE-DEPENDENT ACUTE NEUROTOXICITY
Drug Metab. Dispos., March 1, 2006; 34(3): 389 - 397.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Cheung, A.-M. Yu, C.-S. Chen, K. W. Krausz, L. G. Byrd, L. Feigenbaum, R. J. Edwards, D. J. Waxman, and F. J. Gonzalez
Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1328 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. P. Giacoia, D. L. Birenbaum, H. C. Sachs, and D. R. Mattison
The newborn drug development initiative.
Pediatrics, March 1, 2006; 117(3 Pt 2): S1 - S8.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. Yoon, M. C. Madden, and H. A. Barton
Developmental Expression of Aldehyde Dehydrogenase in Rat: a Comparison of Liver and Lung Development
Toxicol. Sci., February 1, 2006; 89(2): 386 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D.-X. Xu, Y.-H. Chen, J.-P. Wang, M.-F. Sun, H. Wang, L.-Z. Wei, and W. Wei
Perinatal Lipopolysaccharide Exposure Downregulates Pregnane X Receptor and Cyp3a11 Expression in Fetal Mouse Liver
Toxicol. Sci., September 1, 2005; 87(1): 38 - 45.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
K. Allegaert, B. J. Anderson, R. Verbesselt, A. Debeer, J. de Hoon, H. Devlieger, J. N. Van Den Anker, and D. Tibboel
Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity
Br. J. Anaesth., August 1, 2005; 95(2): 231 - 239.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A.-M. Yu, K. Fukamachi, K. W. Krausz, C. Cheung, and F. J. Gonzalez
Potential Role for Human Cytochrome P450 3A4 in Estradiol Homeostasis
Endocrinology, July 1, 2005; 146(7): 2911 - 2919.
[Abstract] [Full Text] [PDF]

Home page
 International Journal of ToxicologyHome page
D. Desaulniers, G. M. Cooke, K. Leingartner, K. Soumano, J. Cole, J. Yang, M. Wade, and A. Yagminas
Effects of Postnatal Exposure to a Mixture of Polychlorinated Biphenyls, p,p'-dichlorodiphenyltrichloroethane, and p-p'-dichlorodiphenyldichloroethene in Prepubertal and Adult Female Sprague-Dawley Rats
International Journal of Toxicology, March 1, 2005; 24(2): 111 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
G. Virkel, A. Lifschitz, J. Sallovitz, A. Pis, and C. Lanusse
COMPARATIVE HEPATIC AND EXTRAHEPATIC ENANTIOSELECTIVE SULFOXIDATION OF ALBENDAZOLE AND FENBENDAZOLE IN SHEEP AND CATTLE
Drug Metab. Dispos., May 1, 2004; 32(5): 536 - 544.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
I. Azorin, M. Portoles, P. Marin, F. Lazaro-Dieguez, L. Megias, G. Egea, and J. Renau-Piqueras
PRENATAL ETHANOL EXPOSURE ALTERS THE CYTOSKELETON AND INDUCES GLYCOPROTEIN MICROHETEROGENEITY IN RAT NEWBORN HEPATOCYTES
Alcohol Alcohol., May 1, 2004; 39(3): 203 - 212.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. G. McCarver
Applicability of the Principles of Developmental Pharmacology to the Study of Environmental Toxicants
Pediatrics, April 1, 2004; 113(4/S1): 969 - 972.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. Ginsberg, D. Hattis, R. Miller, and B. Sonawane
Pediatric Pharmacokinetic Data: Implications for Environmental Risk Assessment for Children
Pediatrics, April 1, 2004; 113(4/S1): 973 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. G. Costa, L. Steardo, and V. Cuomo
Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects
Pharmacol. Rev., March 1, 2004; 56(1): 103 - 147.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. B. Koukouritaki, J. R. Manro, S. A. Marsh, J. C. Stevens, A. E. Rettie, D. G. McCarver, and R. N. Hines
Developmental Expression of Human Hepatic CYP2C9 and CYP2C19
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 965 - 974.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Murayama, A. Soyama, Y. Saito, Y. Nakajima, K. Komamura, K. Ueno, S. Kamakura, M. Kitakaze, H. Kimura, Y.-i. Goto, et al.
Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 300 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D. Desaulniers, K. Leingartner, B. Musicki, A. Yagminas, G.-H. Xiao, J. Cole, L. Marro, M. Charbonneau, and B. K. Tsang
Effects of Postnatal Exposure to Mixtures of Non-ortho-PCBs, PCDDs, and PCDFs in Prepubertal Female Rats
Toxicol. Sci., October 1, 2003; 75(2): 468 - 480.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. L. Kearns, S. M. Abdel-Rahman, S. W. Alander, D. L. Blowey, J. S. Leeder, and R. E. Kauffman
Developmental Pharmacology -- Drug Disposition, Action, and Therapy in Infants and Children
N. Engl. J. Med., September 18, 2003; 349(12): 1157 - 1167.
[Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Wilkening, F. Stahl, and A. Bader
COMPARISON OF PRIMARY HUMAN HEPATOCYTES AND HEPATOMA CELL LINE HEPG2 WITH REGARD TO THEIR BIOTRANSFORMATION PROPERTIES
Drug Metab. Dispos., August 1, 2003; 31(8): 1035 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
C. A. McQueen and B. Chau
Neonatal Ontogeny of Murine Arylamine N-Acetyltransferases: Implications for Arylamine Genotoxicity
Toxicol. Sci., June 1, 2003; 73(2): 279 - 286.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. G. McCarver and R. N. Hines
The Ontogeny of Human Drug-Metabolizing Enzymes: Phase II Conjugation Enzymes and Regulatory Mechanisms
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 361 - 366.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.